Studies on a new series of THA analogues: Effects of the aromatic residues that line the gorge of AChE  by Pomponi, Massimo et al.
FEBS 18637 FEBS Letters 409 (1997) 155-160 
Studies on a new series of THA analogues: Effects of the aromatic 
residues that line the gorge of AChE 
Massimo Pomponia*, Maurizio Martaa, Annalisa Colellaa, Silvia Sacchia, Maria Patamiab, 
Franco Gattac, Francesca Caponed, Alberto OHveriod, Flaminia Pavone6 
^Istituto di Chimica e Chimica Clínica, Facoltä di Medicina, UCSC, Rome, Italy 
hCentro Chimica dei Recettori, CNR, Rome, Italy 
c Laboratorio Chimica del Fármaco, Istituto Superiore di Sanitá, Rome, Italy 
dDipartimento di Genética e Biología Molecolare dell'Universitá 'La Sapienza', Rome, Italy 
"Istituto di Psicobiologia e Psicofarmacologia CNR, Rome, Italy 
Received 9 January 1997; revised version received 7 April 1997 
Abstract A series of N-monoalkylsubstituted 1,2,3,4-tetrahy-
dro-9-aminoacridines have been prepared after modelling simula-
tion of the AChE-inhibitor complex. Molecular modelling has 
predicted a number of hydrophobic residues to be involved in the 
catalytic mechanism of this interaction between the binding sites 
of AChE and this series of aminoacridines. In these compounds 
the acridine moiety becomes sandwiched between the rings of 
PHE330 and TRP84. In particular, the alkyl chain shows the 
important role of aromatic groups as binding sites. Their in vitro 
inhibitory properties (enzyme from Electrophorus electricus) 
confirm the aromatic groups as a general and significant 
characteristic of the mechanism of AChE inhibition. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The main biological role of acetylcholinesterase (AChE) is 
the termination of neurotransmission at cholinergic synapses 
by rapid hydrolysis of acetylcholine. A C h E inhibitors are very 
important for the symptomatic treatment of diseases associ-
ated with acetylcholine depletion [1]. Particularly, two A C h E 
inhibitors, physostigmine and 1,2,3,4-tetrahydro-9-aminoacri-
dine (THA) are employed in the therapeutic approach to se-
nile dementia of Alzheimer type. 
Since 1986 our group [2-4] reported the inhibitory effects of 
a series of physostigmine derivatives; these compounds carba-
moylate the esteraste site of A C h E with a mechanism typical 
of irreversible inhibitors. The values of their bimolecular rate 
constants have suggested the existence of a hydrophobic in-
teraction in an area adjacent to the esteraste site of the en-
zyme. Also the reversible competitive inhibitor T H A [5] inter-
acts with the active site of A C h E ; in the inhibitor-enzyme 
complex T H A is sandwiched between the rings of PHE330 
and TRP84 ; the last ring has been identified as part of the 
putative anionic (choline) binding site [6]. 
The hypothesis of the present study was to verify if an 
equivalent hydrophobic interaction is also operating for rever-
sible T H A analogues. In order to answer this question, we 
have studied a number of TV-monoalkylsubstituted 1,2,3,4-tet-
rahydro-9-aminoacridines as probes in the docking with 
A C h E from Torpedo californica. According to the results of 
the docking simulation we have selected and prepared a series 
of these inhibitors whose anticholinesterase activity in vitro 
has been investigated. 
2. Materials and methods 
2.1. Monoalkylsubstituted 1,2,3,4-tetrahydro-9-aminoacridines 
Compounds were synthesized by heating a mixture of 9-chloro-
1,2,3,4-tetrahydroacridine (10.9 g, 0.05 mol) and n-alkylamine (0.12 
mol) in phenol (50 g) at 125-130°C for 5 h, [7]. Their identities were 
confirmed by spectroscopic methods. For nuclear magnetic resonance 
(NMR) spectra each compound was dissolved in CDCI3. Trimethyl-
silane was included as an internal standard. The 1H- (300 MHz) and 
13C-NMR (75.5 MHz) were obtained on a Varían Gemini spectrom-
eter (Fig. 1A,B). 
2.2. Enzyme inhibition in vitro 
All reagents were purchased from Sigma Chemical Co. (St. Louis, 
MO). AChE activity from Electrophorus electricus was determined by 
the colorimetric method of [8] using acetylthiocholine as substrate. 
The assay medium contained 0.5 mM acetylthiocholine iodide, 0.25 
mM dithio-bis-dinitrobenzoic acid, 0.1 M sodium phosphate, pH 8.0, 
and the reaction was monitored at 410 nm by means of graphics 
software (Varían Cary 3E) at 25° using thermostated (Haake) cells. 
The Michaelis constant (Km) at 25°C had been determined previously 
(average ± S.D., 0.14 ±0.0007 mM). Each experiment was repeated 
3 times. Samples were assayed in the absence of inhibitor and served 
as control. The inhibitor competitive constant (AT¡) for each THA 
derivative was determined from the relationship between the K¡ and 
the concentration of inhibitor which causes 50% inhibition (IC50) of 
the competitive enzymatic reaction, according to the formula: 
IC50 = Äi(l+[S]/A:m)[9]. 
2.3. Molecular modelling 
The X-ray crystallographic coordinates (at 2.8 A resolution, entry 
1ACJ) for AChE from Torpedo californica [10] were obtained from 
the Brookhaven Protein Data Bank [11]. Optimization was carried out 
with the special method used by ANNEAL (hot region, 10 A; inter-
esting region, 16 A). The POWELL minimizer, which belongs to the 
conjugate gradient family of minimization methods, was selected. The 
TRYPOS force field consisted of only non-bonded energies: hydro-
gen-bonding, van der Waals, torsional and bending energy terms; the 
electrostatic term was ignored. The cut-off criterion was 8 A radius for 
all interactions. The energy convergence criterion was ±0.05 
kcal-mol-1. 
The structure of THA analogues was built by using SYBYL. The 
geometry of the enzyme-inhibitor complex was adjusted according to 
the crystallographic structures previously reported [5,10]. 
3. Results and discussion 
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In this investigation we used for our fit model the A C h E 
from Torpedo californica. [5,10]. This enzyme has a simpler 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 0 4 9 2 - 4 
156 M. Pomponi et al.lFEBS Letters 409 (1997) 155-160 
Fig. 1. Nuclear magnetic resonance spectrum of octyl-THA. A: The :H-
ating at 300 MHz. The assignment of each NMR signal to the pertinent 
MHz 13C NMR spectrum for the same sample; APT assignments. 
quaternary structure (homodimer) than AChE from Electro-
phorus, for which the three-dimensional structure has not yet 
been determined, although a preliminary characterisation has 
been reported [12]. Fig. 2A shows the stereoview of conserved 
aromatics in the active site gorge, the catalytic triad (Ser200-
His440-Glu327) and the inhibitor molecule. The most remark-
able feature of this figure is the long and narrow alkyl chain 
which penetrates halfway into the enzyme. The molecular me-
and 13C-NMR were obtained on a Varian Gemini spectrometer oper-
proton and carbon was achieved by HETCOR measurements. B: 75.5-
chanics simulation of Torpedo AChE-inhibitor complex 
shows, in addition, that the planar tacrine moiety is placed 
between the aromatic rings of PHE330 and TRP84 (Fig. 
2B,C). On the other hand, the residues that line the 'aromatic 
gorge' also play an important role [5] in the formation of this 
complex, by an additional binding hydrophobic effect that, for 
THA analogues, is greater for heptyl and octyl chains. 
Following this simulation, THA analogues produce a mod-
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Fig. 2. The crystal structure of AChE, complexed with tacrine [5,10] was used as the basis for modelling procedures. Octyl-THA was modelled 
and minimized using Sybyl program. A: Stereo drawing that includes the residues contributing to the active site gorge interaction (Brookhaven 
Protein Data Base, entry 1ACJ). The AChE inhibitor, octyl-THA, is red-coloured. B: Stereo drawing of a thin slice through the AChE (mono-
mer). The red-dot van der Waals surface shows the narrow gorge and the active site; the yellow dot shows the van der Waals surface of octyl-
THA. C: Space-filling stereo view of the complex between AChE and octyl-THA. 
ulation of the anti-AChE activity, as already reported for 
irreversible inhibitors [12,13,4]. Furthermore, it is interesting 
to note that the effect of binding interaction between the alkyl 
chain and the aromatic residues modulates the interaction 
between the acridine ring of THA analogues with the 
PHE330 aromatic ring (Fig. 3). 
These results have been confirmed also by the enzyme in-
hibition in vitro (Fig. 4) which is stronger for heptyl- and 
octyl-THA. The non-linear characteristic relationship between 
the number of carbon atoms and K\ values suggests that the 
conformational distortion of AChE is small. In fact, the mod-
ulation of the inhibitory effect can be justified by the presence 
of aromatic residues which fill a substantial portion of the 
surface of the gorge. It has been also noted by the present 
modelling studies that the binding interaction of the chain, 
due to an enhancement of the steric effect, decreases in the 
case of the decyl analogue. Moreover, these studies in vitro 
show that also for reversible inhibitors the activity is modu-
lated by the length of the «-alkyl chain and suggest that future 
inhibition and reactivation data may be reasonably antici-
pated. 
From a biochemical point of view, this study shows that the 
K¡ of THA analogues is principally affected by three factors: 
(a) the interactions between enzyme molecule and the planar 
tacrine ring; (b) the high aromatic content of the walls of the 
active site gorge, which may help explain previous biochem-
ical studies of homologous series of organophosphorus [13] 
and carbamic [4] inhibitors; (c) the steric effects which, for 
longer residues, as in the example of decyl, reduce the con-
formational fitting of the alkyl chain which projects inside the 
aromatic gorge of the enzyme. In fact, if only the steric effects 
were acting for all the analogues, the THA derivatives should 
have a constant decrease, proportional to the length of the 
alkyl chain, of the inhibitory activity. On the contrary, the 
high affinity of octyl- and heptyl-THA for the enzyme sug-
gests that some hydrophobic interactions successfully antago-
nize the steric effect introduced in the THA molecule by the 
alkyl radical. 
Finally, it would appear from preliminary results that octyl-
THA is less toxic than THA whose toxicity has been reported 
in the literature [15] to be > 20 mg/kg; in fact, in experiments 
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Fig. 3. Interaction between inhibitor acridine rings and PHE330 aromatic ring. Decyl-THA, black; octyl-THA, red; propyl-THA, blue; and 
THA, green colour. For octyl-THA the PHE330 aromatic ring rotates (29°) with respect to THA complex; for propyl-THA the rotation (—9°) 
causes a decrease in binding. 
in which the acute toxicity was measured in CD-I mice strain 
the LD50 of octyl-THA was > 31 mg/kg. 
2 4 
n. of carbon atoms of the alkyl chain 
Fig. 4. Effect of alkyl-chain on competitive inhibition constant (K\). 
In conclusion, in view of the growing interest in new agents 
for the therapeutic treatment of Alzheimer's disease [14] octyl-
or heptyl-THA could provide an attractive approach in the 
search for additional cholinergic compounds. 
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